• Explore /
  • Poster
  • / A phase I study in patients with a human papillomavirus type 16 positive oropharyngeal tumor treated with second generation synthetic long peptide vaccine conjugated to a defined adjuvant.

A phase I study in patients with a human papillomavirus type 16 positive oropharyngeal tumor treated with second generation synthetic long peptide vaccine conjugated to a defined adjuvant.

Abstract Poster

Authors

null

Marije Slingerland

Leiden University Medical Center, Leiden, Netherlands

Marije Slingerland , Frank Speetjens , Marij Welters , Hans Gelderblom , Inge Roozen , Lilly-Ann van der Velden , Cornelis Joseph Melief , Maarten Zandvliet , Sjoerd van der Burg , Ferry Ossendorp

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Vaccines

Clinical Trial Registration Number

2014-000658-12

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS3113)

DOI

10.1200/JCO.2016.34.15_suppl.TPS3113

Abstract #

TPS3113

Poster Bd #

426a

Abstract Disclosures

Similar Posters

First Author: Matthew P Morrow

First Author: Frank M. Speetjens

First Author: Mayumi Nakagawa

First Author: Christine H. Chung